Tango Therapeutics Inc (TNGX NASDAQ) stock market data APIs
$21.4199
-0.72(-3.4%)
as of November 6, 2026
Try our APIs with
free plan!
Tango Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Prev. Close
21.4199
Open
20.701
High
22.2509
Low
20.5885
52 wk Range
7.49-34.39
Market Cap
3 625 M
Shares Outstanding
169 M
Revenue
53 811 K
EPS
0.13
Beta
1.223
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Tango Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tango Therapeutics Inc data using free add-ons & libraries
Get Tango Therapeutics Inc Fundamental Data
Tango Therapeutics Inc Fundamental data includes:
- Net Revenue: 53 811 K
- EBITDA: -134 424 992
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-11-10
- EPS/Forecast: -0.34
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tango Therapeutics Inc News
New
Most and least shorted mid- to mega-cap healthcare stocks at the end of October
Short interest data from late October 2026 highlights deeply divided investor sentiment across the healthcare sector. Strong bearish bets remain heavily concentrated in high-volatility biotechnology, ...
TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data
Tango Therapeutics TNGX shares fell 16.4% on Friday after updated phase I/II study data for vopimetostat plus daraxonrasib in previously treated pancreatic cancer showed an 82% objective response rate...
Tango Therapeutics Just Improved On This 'Unprecedented' Cancer Drug
Tango Therapeutics beat expectations Friday for its combination using Revolution Medicines' newly approved drug in pancreatic cancer. Continue Reading
Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?
Tango Therapeutics Inc.(NASDAQ:TNGX) on Friday shared Phase 1/2 trial data for its investigational drug vopimetostat, revealing strong efficacy in treating advanced pancreatic and lung cancers. The b...
Get Tango Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.